Investor

Overview

Unlocking Value and Delivering Shareholder Returns with Holdings in Growth Sectors Worldwide

For over 25 years, DSS, Inc. (NYSE American: DSS) has protected corporations, financial institutions, and governments from sophisticated and costly fraud. In 2019, we began a major transformation.

Today, we take ownership positions or fully acquire businesses in five high-growth sectors to monetize our holdings by:

  1. Transitioning the company's revenue streams into exponential and emerging new business lines.
  2. Operating the company to create growth opportunities and scalable/recurring revenue.
  3. Restructuring and Developing our assets to position them for growth and potential monetization.

Our Strategy delivers shareholder value by:

  1. Developing solid revenue growth, increasing profitability, growing assets which will drive stock price and market cap.
  2. Building long-term shareholder values by increasing assets through mergers and acquisitions.
  3. Providing a unique dividend structure to build value, and monetize assets for investors.

Stock Data

DSS DSS, Inc. - NYSE

SEC Filings

All Filings
Annual
Quarterly
Current Reports
Ownership
Filing Date
Form Type
Description

Investor FAQS

Updated May 17th, 2022

  • Expand All
How many shares are outstanding?
84,626,847
How many shares are in float?
57,546,000
What is the insider ownership percentage?
~31.3% - Based on the information provided in the most recently published 10-K.
How many shares does Executive Chairman of the Board Mr. Heng Chan own?
~31.3% - Based on the information provided in the most recently published 10-K.
How much capital has the company raised over the last 12 months?
$179.2 million
How has the company deployed the capital that it raised in the last 12 months?
Please refer to our latest news & Press Releases which can be found here: https://www.dssworld.com/investor.html
What is the status of the Impact Biomedical IPO and issuance of the dividend shares?
S-1 is filed. Offering planned for late 2022, contingent on market conditions.
How many shares of Impact Biomedical will DSS shareholders receive when they IPO?
Shareholders will receive 4 shares of Impact Biomedical for each DSS share held except for related parties.
What products are closest to commercialization in the Impact Biomedical pipeline?
Impact Biomedical has a broad portfolio of technologies and products that range from development to commercial stage. Examples of products closer to commercialization include probiotics and air purification.
What is the primary business of DSS today?
DSS, Inc. is a multinational company operating business segments in product packaging, biotechnology, direct marketing, commercial lending, securities and investment management, alternative trading, digital transformation, secure living, and alternative energy. Its business model is based on a distribution sharing system in which shareholders receive shares in its subsidiaries as DSS strategically unlocks value through IPO spin-offs. Under new leadership, DSS has built the necessary foundation for sustainable growth through the acquisition and formation of a diversified portfolio of companies positioned to drive profitability in five high-growth sectors. These companies offer innovative, flexible, and real-world solutions that not only meet customer needs but create sustainable value and opportunities for transformation.
What is the breakdown of revenue from the different divisions?
See the 05/16/2021 10-Q found here: https://www.dssworld.com/investor.html

Download our

Investor Presentation

View our investor presentation report for additional information on DSS, Inc.

Download Download

Press Releases

Overview

Overview

Unlocking Value and Delivering Shareholder Returns with Holdings in Growth Sectors Worldwide

For over 25 years, DSS, Inc. (NYSE American: DSS) has protected corporations, financial institutions, and governments from sophisticated and costly fraud. In 2019, we began a major transformation.

Today, we take ownership positions or fully acquire businesses in five high-growth sectors to monetize our holdings by:

  1. Transitioning the company's revenue streams into exponential and emerging new business lines.
  2. Operating the company to create growth opportunities and scalable/recurring revenue.
  3. Restructuring and Developing our assets to position them for growth and potential monetization.

Our Strategy delivers shareholder value by:

  1. Developing solid revenue growth, increasing profitability, growing assets which will drive stock price and market cap.
  2. Building long-term shareholder values by increasing assets through mergers and acquisitions.
  3. Providing a unique dividend structure to build value, and monetize assets for investors.
Stock Data
DSS DSS, Inc. - NYSE
SEC Filings
All Filings
Annual
Quarterly
Current Reports
Ownership
Filing Date
Form Type
Description
Investor FAQS

Updated May 17th, 2022

How many shares are outstanding?
84,626,847
How many shares are in float?
57,546,000
What is the insider ownership percentage?
~31.3% - Based on the information provided in the most recently published 10-K.
How many shares does Executive Chairman of the Board Mr. Heng Chan own?
~31.3% - Based on the information provided in the most recently published 10-K.
How much capital has the company raised over the last 12 months?
$179.2 million
How has the company deployed the capital that it raised in the last 12 months?
Please refer to our latest news & Press Releases which can be found here: https://www.dssworld.com/investor.html
What is the status of the Impact Biomedical IPO and issuance of the dividend shares?
S-1 is filed. Offering planned for late 2022, contingent on market conditions.
How many shares of Impact Biomedical will DSS shareholders receive when they IPO?
Shareholders will receive 4 shares of Impact Biomedical for each DSS share held except for related parties.
What products are closest to commercialization in the Impact Biomedical pipeline?
Impact Biomedical has a broad portfolio of technologies and products that range from development to commercial stage. Examples of products closer to commercialization include probiotics and air purification.
What is the primary business of DSS today?
DSS, Inc. is a multinational company operating business segments in product packaging, biotechnology, direct marketing, commercial lending, securities and investment management, alternative trading, digital transformation, secure living, and alternative energy. Its business model is based on a distribution sharing system in which shareholders receive shares in its subsidiaries as DSS strategically unlocks value through IPO spin-offs. Under new leadership, DSS has built the necessary foundation for sustainable growth through the acquisition and formation of a diversified portfolio of companies positioned to drive profitability in five high-growth sectors. These companies offer innovative, flexible, and real-world solutions that not only meet customer needs but create sustainable value and opportunities for transformation.
What is the breakdown of revenue from the different divisions?
See the 05/16/2021 10-Q found here: https://www.dssworld.com/investor.html
Does the company plan to raise more capital and if so, at what level?
Not planned in the immediate future.
Investor Presentation

Download our

Investor Presentation

View our investor presentation report for additional information on DSS, Inc.

Download Download
Press

Press Releases